Palvella Therapeutics, Inc. (PVLA) Change in Cash (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed Change in Cash for 12 consecutive years, with $69.4 million as the latest value for Q4 2024.
- On a quarterly basis, Change in Cash rose 2442.84% to $69.4 million in Q4 2024 year-over-year; TTM through Dec 2024 was $76.3 million, a 976.16% increase, with the full-year FY2024 number at $76.3 million, up 976.16% from a year prior.
- Change in Cash was $69.4 million for Q4 2024 at Palvella Therapeutics, up from -$330000.0 in the prior quarter.
- In the past five years, Change in Cash ranged from a high of $69.4 million in Q4 2024 to a low of -$34.0 million in Q1 2022.
- A 5-year average of $2.2 million and a median of -$2.0 million in 2023 define the central range for Change in Cash.
- Peak YoY movement for Change in Cash: crashed 844.93% in 2022, then surged 2442.84% in 2024.
- Palvella Therapeutics' Change in Cash stood at $3.5 million in 2020, then plummeted by 305.53% to -$7.3 million in 2021, then crashed by 34.3% to -$9.8 million in 2022, then skyrocketed by 69.74% to -$3.0 million in 2023, then soared by 2442.84% to $69.4 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's Change in Cash are $69.4 million (Q4 2024), -$330000.0 (Q3 2024), and $8.3 million (Q2 2024).